The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
15 | 13 | 17 | 29 |
Growth
|
79 | 87 | 25 | 31 |
Safety
|
83 | 77 | 79 | 65 |
Sentiment
|
34 | 77 | 32 | 1 |
|
65 | 79 | 16 | 5 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Analyst Opinions
|
52 | 74 | 43 | 13 |
Opinions Change
|
31 | 94 | 50 | 50 |
Pro Holdings
|
n/a | 54 | 77 | 49 |
Market Pulse
|
17 | 46 | 7 | 5 |
Sentiment
|
34 | 77 | 32 | 1 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
15 | 13 | 17 | 29 |
Growth
|
79 | 87 | 25 | 31 |
|
83 | 77 | 79 | 65 |
Combined
|
70 | 77 | 19 | 25 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Price vs. Sales (P/S)
|
17 | 19 | 12 | 20 |
Price vs. Earnings (P/E)
|
3 | 1 | 12 | 16 |
Price vs. Book (P/B)
|
7 | 5 | 10 | 7 |
Dividend Yield
|
67 | 56 | 74 | 76 |
Value
|
15 | 13 | 17 | 29 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue Growth
|
62 | 44 | 28 | 10 |
Profit Growth
|
45 | 92 | 45 | 88 |
Capital Growth
|
87 | 65 | 25 | 7 |
Stock Returns
|
61 | 77 | 71 | 53 |
Growth
|
79 | 87 | 25 | 31 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Leverage
|
93 | 92 | 90 | 82 |
Refinancing
|
24 | 18 | 26 | 22 |
Liquidity
|
94 | 92 | 92 | 80 |
|
83 | 77 | 79 | 65 |
Discover high‑ranked alternatives to GlaxoSmithKline Pharmaceuticals and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.